Lumenis Announces UltraPulse® with SCAAR FX™ Clinical Data to be Presented at the 16th European Burns Association Congress
September 16, 2015 – Hanover, Germany
Lumenis Ltd. (NASDAQ: LMNS), the world’s largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, announced today that two oral presentations showing the benefit of the UltraPulse® in the treatment of patients with severe burn injuries will be presented at the 16th European Burns Association (EBA) Congress, taking place September 16 -19, 2015 in Hannover, Germany.
“In the past decade and a half, there have been major strides in the management of severe scars, especially with the increased adoption of laser therapy approaches,” said Gerd Gauglitz, MD, dermatologist at the Department of Dermatology and Allergology, Ludwig Maximilians University, Munich, Germany. “Laser scar therapy, particularly fractional ablative laser resurfacing, has proven to be a significant advancement in scar treatment and management and has been progressively embraced as a promising tool in the multidisciplinary treatment of complex burns and traumatic scars.”
At the forefront of laser solutions, the UltraPulse with SCAAR FX™, which was designed to treat everyday to complex skin conditions, features a range of full ablative, fractional ablative, and incisional modalities for treating damaged tissue. The laser platform features the Gold Standard UltraPulse® technology, enabling a deep and safe impact during treatments of scars leading to unique efficacy combined with optimal safety margins
“Before using this laser system, I was often challenged when facing severe scars,” said Matteo Tretti Clementoni, MD, plastic surgeon at the Department of Laser and Surgery at the Istituto Dermatologico Europeo, Milan, Italy. “With the UltraPulse SCAAR FX mode, I am able to offer a minimally invasive procedure that yields excellent results in improving not only the aesthetic aspects of the scars, but also the plaiablity and pain aspects, thereby allowing me to improve the quality of life for my patients with severe burns.”
“For nearly half a century, Lumenis has been committed to providing quality, innovative energy-based technologies,” said Tzipi Ozer-Armon, CEO of Lumenis. “As the only laser solution company attending EBA, we are pleased to take part in this year’s congress and look forward to introducing and discussing these important data with the European burn treatment community.”
Lumenis encourages EBA 2015 attendees to visit booth number 59 throughout the conference to learn more about available laser scar solutions and therapies. A schedule highlighting the company’s two key data presentations are below.
16 September, 16:00 – 17:30
“Why to burn a burn: Advanced fractional CO2 treatment.” (011, Room: Saal 3A)
Matteo Tretti Clementoni
18 September, 14:00 – 15:30
“Objective evaluations on the efficacy of fractional CO2 laser treatment for the improvement of hypertrophic burn scars.” (166, Room: Saal 3A)
In addition to the UltraPulse laser system presentations, Lumenis is offering conference participants the opportunity to receive preceptorships with the top industry experts to learn more about the UltraPulse with SCAAR FX and the AcuPulse®. The experts include Dr. Matteo Tretti Clementoni, Dr. Tapan Patel, and Dr. Gerd Gauglitz. To learn more about the preceptorship opportunity,
please visit: http://information.lumenis.com/eba-2015-lp-0
Lumenis (NASDAQ: LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Lazar Partners Ltd.
Most popular Pages